Darapladib Fails to Reduce Cardiovascular Events

In the prospective, randomized STABILITY trial, lipoprotein-associated phospholipase A2 inhibition did not improve the primary clinical outcomes.

Elevated lipoprotein-associated phospholipase A2 (LpPLA2) levels are associated with plaque vulnerability and an increased risk for ischemic events. Darapladib, a selective oral inhibitor of LpPLA2, might play a role in stabilizing plaque and improving cardiovascular outcomes.

In the double-blind, manufacturer-sponsored STABILITY trial, whose top-line results were reported in 2013, investigators randomized 15,828 patients with stable CHD to receive either once-daily darapladib (160 mg) or placebo, in addition to guideline-recommended care, and followed for a median of 3.7 years. The primary outcome of interest was time to cardiovascular death, myocardial infarction (MI), or stroke. Secondary endpoints included the components of the primary e…

Reviewing Author

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

JoAnne M. Foody, MD

Disclosures

Consultant / Advisory boardAegerion; Amarin; Bristol-Myers Squibb; Janssen; Merck; Pfizer; Sanofi-Aventis; Boehringer Ingelheim

Leadership positions in professional societiesAmerican College of Cardiology, Cardiosmart (Co-chair)

Darapladib Fails to Reduce Cardiovascular Events

Topics

Reviewing Author